These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 30513034)
1. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism. Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E World J Biol Psychiatry; 2020 Jan; 21(1):29-52. PubMed ID: 30513034 [No Abstract] [Full Text] [Related]
2. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Laika B; Leucht S; Heres S; Schneider H; Steimer W Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338 [TBL] [Abstract][Full Text] [Related]
4. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Czerwensky F; Leucht S; Steimer W Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458 [TBL] [Abstract][Full Text] [Related]
5. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Fekete F; Menus Á; Tóth K; Kiss ÁF; Minus A; Sirok D; Belič A; Póti Á; Csukly G; Monostory K Sci Rep; 2023 Oct; 13(1):18507. PubMed ID: 37898643 [TBL] [Abstract][Full Text] [Related]
6. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169 [TBL] [Abstract][Full Text] [Related]
7. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047 [TBL] [Abstract][Full Text] [Related]
8. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460 [TBL] [Abstract][Full Text] [Related]
9. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389 [TBL] [Abstract][Full Text] [Related]
10. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Okubo M; Narita M; Murayama N; Akimoto Y; Goto A; Yamazaki H Hum Psychopharmacol; 2016 Mar; 31(2):83-92. PubMed ID: 26856397 [TBL] [Abstract][Full Text] [Related]
11. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090 [TBL] [Abstract][Full Text] [Related]
12. The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. Hattori S; Suda A; Miyauchi M; Shiraishi Y; Saeki T; Fukushima T; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Saigusa Y; Kishida I BMC Psychiatry; 2020 Feb; 20(1):72. PubMed ID: 32070304 [TBL] [Abstract][Full Text] [Related]
13. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Hägg S; Spigset O; Lakso HA; Dahlqvist R Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614 [TBL] [Abstract][Full Text] [Related]
14. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441 [TBL] [Abstract][Full Text] [Related]
15. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Plesnicar BK; Zalar B; Breskvar K; Dolzan V J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753 [TBL] [Abstract][Full Text] [Related]
16. Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients. Palatini P; Benetti E; Mos L; Garavelli G; Mazzer A; Cozzio S; Fania C; Casiglia E Eur J Epidemiol; 2015 Mar; 30(3):209-17. PubMed ID: 25595320 [TBL] [Abstract][Full Text] [Related]
17. Coffee, CYP1A2 genotype, and risk of myocardial infarction. Cornelis MC; El-Sohemy A; Kabagambe EK; Campos H JAMA; 2006 Mar; 295(10):1135-41. PubMed ID: 16522833 [TBL] [Abstract][Full Text] [Related]
18. Association study between functional polymorphisms in the cytochrome P450 1A2 and 2D6 genes and polydipsia in schizophrenia. Matsumoto C; Shinkai T; De Luca V; Hori H; Hwang R; Ohmori O; Kennedy JL; Nakamura J Neuromolecular Med; 2006; 8(3):381-8. PubMed ID: 16775389 [TBL] [Abstract][Full Text] [Related]
19. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. Melkersson KI; Scordo MG; Gunes A; Dahl ML J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978 [TBL] [Abstract][Full Text] [Related]
20. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. Palatini P; Ceolotto G; Ragazzo F; Dorigatti F; Saladini F; Papparella I; Mos L; Zanata G; Santonastaso M J Hypertens; 2009 Aug; 27(8):1594-601. PubMed ID: 19451835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]